<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font3" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font4" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="2" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font6" size="15" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="16" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="16" family="SymbolMT" color="#000000"/>
	<fontspec id="font9" size="12" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font10" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font11" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font12" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font13" size="9" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font14" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font15" size="9" family="SymbolMT" color="#000000"/>
	<fontspec id="font16" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font17" size="10" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font18" size="10" family="SymbolMT" color="#000000"/>
<text top="85" left="477" width="78" height="10" font="font0" id="p1_t1" reading_order_no="2" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="42" left="315" width="62" height="7" font="font1" id="p1_t2" reading_order_no="0" segment_no="0" tag_type="text"><b>Available online</b></text>
<text top="42" left="380" width="176" height="7" font="font3" id="p1_t3" reading_order_no="1" segment_no="0" tag_type="text">http://breast-cancer-research.com/content/7/1/R60</text>
<text top="735" left="569" width="14" height="8" font="font4" id="p1_t4" reading_order_no="144" segment_no="23" tag_type="text">R60</text>
<text top="85" left="57" width="9" height="2" font="font5" id="p1_t5" reading_order_no="4" segment_no="2" tag_type="title">Vol 7 No 1</text>
<text top="85" left="57" width="103" height="14" font="font6" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="title">Research article</text>
<text top="102" left="57" width="426" height="14" font="font7" id="p1_t7" reading_order_no="5" segment_no="3" tag_type="title"><b>Prenylation inhibitors stimulate both estrogen receptor </b></text>
<text top="97" left="483" width="10" height="20" font="font8" id="p1_t8" reading_order_no="6" segment_no="3" tag_type="title">α</text>
<text top="120" left="57" width="457" height="14" font="font7" id="p1_t9" reading_order_no="7" segment_no="3" tag_type="title"><b>transcriptional activity through AF-1 and AF-2 and estrogen </b></text>
<text top="138" left="57" width="68" height="14" font="font7" id="p1_t10" reading_order_no="8" segment_no="3" tag_type="title"><b>receptor </b></text>
<text top="133" left="125" width="9" height="20" font="font8" id="p1_t11" reading_order_no="9" segment_no="3" tag_type="title">β</text>
<text top="138" left="134" width="174" height="14" font="font7" id="p1_t12" reading_order_no="10" segment_no="3" tag_type="title"><b> transcriptional activity</b></text>
<text top="156" left="57" width="81" height="11" font="font9" id="p1_t13" reading_order_no="11" segment_no="4" tag_type="text">Philippe Cestac</text>
<text top="155" left="138" width="5" height="8" font="font3" id="p1_t14" reading_order_no="12" segment_no="4" tag_type="text">1</text>
<text top="156" left="143" width="134" height="11" font="font9" id="p1_t15" reading_order_no="13" segment_no="4" tag_type="text">, Guillaume Sarrabayrouse</text>
<text top="155" left="277" width="5" height="8" font="font3" id="p1_t16" reading_order_no="14" segment_no="4" tag_type="text">1</text>
<text top="156" left="282" width="132" height="11" font="font9" id="p1_t17" reading_order_no="15" segment_no="4" tag_type="text">, Claire Médale-Giamarchi</text>
<text top="155" left="414" width="5" height="8" font="font3" id="p1_t18" reading_order_no="16" segment_no="4" tag_type="text">1</text>
<text top="156" left="419" width="91" height="11" font="font9" id="p1_t19" reading_order_no="17" segment_no="4" tag_type="text">, Philippe Rochaix</text>
<text top="155" left="510" width="5" height="8" font="font3" id="p1_t20" reading_order_no="18" segment_no="4" tag_type="text">1</text>
<text top="156" left="515" width="6" height="11" font="font9" id="p1_t21" reading_order_no="19" segment_no="4" tag_type="text">, </text>
<text top="172" left="57" width="84" height="11" font="font9" id="p1_t22" reading_order_no="20" segment_no="4" tag_type="text">Patrick Balaguer</text>
<text top="171" left="141" width="5" height="8" font="font3" id="p1_t23" reading_order_no="21" segment_no="4" tag_type="text">2</text>
<text top="172" left="146" width="66" height="11" font="font9" id="p1_t24" reading_order_no="22" segment_no="4" tag_type="text">, Gilles Favre</text>
<text top="171" left="212" width="5" height="8" font="font3" id="p1_t25" reading_order_no="23" segment_no="4" tag_type="text">1</text>
<text top="172" left="217" width="99" height="11" font="font9" id="p1_t26" reading_order_no="24" segment_no="4" tag_type="text">, Jean-Charles Faye</text>
<text top="171" left="316" width="5" height="8" font="font3" id="p1_t27" reading_order_no="25" segment_no="4" tag_type="text">1</text>
<text top="172" left="321" width="144" height="11" font="font9" id="p1_t28" reading_order_no="26" segment_no="4" tag_type="text"> and Sophie Doisneau-Sixou</text>
<text top="171" left="465" width="5" height="8" font="font3" id="p1_t29" reading_order_no="27" segment_no="4" tag_type="text">1</text>
<text top="205" left="57" width="3" height="5" font="font10" id="p1_t30" reading_order_no="28" segment_no="5" tag_type="text">1</text>
<text top="205" left="60" width="489" height="7" font="font3" id="p1_t31" reading_order_no="29" segment_no="5" tag_type="text">Département 'Innovation Thérapeutique et Oncologie Moléculaire', Centre de Physiopathologie de Toulouse Purpan, INSERM U563 and Institut </text>
<text top="215" left="57" width="121" height="7" font="font3" id="p1_t32" reading_order_no="30" segment_no="5" tag_type="text">Claudius Regaud, Toulouse, France</text>
<text top="224" left="57" width="3" height="5" font="font10" id="p1_t33" reading_order_no="31" segment_no="6" tag_type="text">2</text>
<text top="224" left="60" width="299" height="7" font="font3" id="p1_t34" reading_order_no="32" segment_no="6" tag_type="text">INSERM 540, Endocrinologie Moléculaire et Cellulaire des Cancers, Montpellier, France</text>
<text top="242" left="57" width="224" height="7" font="font3" id="p1_t35" reading_order_no="33" segment_no="7" tag_type="text">Corresponding author: Sophie Doisneau-Sixou, sixou@icr.fnclcc.fr</text>
<text top="260" left="57" width="485" height="7" font="font3" id="p1_t36" reading_order_no="34" segment_no="8" tag_type="text">Received: 23 Jul 2004 Revisions requested: 17 Sep 2004 Revisions received: 22 Sep 2004 Accepted: 4 Oct 2004 Published: 8 Nov 2004</text>
<text top="279" left="57" width="65" height="7" font="font11" id="p1_t37" reading_order_no="35" segment_no="9" tag_type="text"><i>Breast Cancer Res</i></text>
<text top="279" left="122" width="25" height="7" font="font3" id="p1_t38" reading_order_no="36" segment_no="9" tag_type="text"> 2005, </text>
<text top="279" left="147" width="4" height="7" font="font2" id="p1_t39" reading_order_no="37" segment_no="9" tag_type="text"><b>7</b></text>
<text top="279" left="152" width="115" height="7" font="font3" id="p1_t40" reading_order_no="38" segment_no="9" tag_type="text">:R60-R70 (DOI 10.1186/bcr956)</text>
<text top="283" left="266" width="44" height="2" font="font5" id="p1_t41" reading_order_no="39" segment_no="9" tag_type="text">http://breast-cancer-research.com/content/7/1/R60</text>
<text top="289" left="57" width="54" height="7" font="font3" id="p1_t42" reading_order_no="40" segment_no="10" tag_type="text">© 2004 Cestac</text>
<text top="289" left="111" width="17" height="7" font="font11" id="p1_t43" reading_order_no="41" segment_no="10" tag_type="text"><i> et al</i></text>
<text top="289" left="128" width="107" height="7" font="font3" id="p1_t44" reading_order_no="42" segment_no="10" tag_type="text">., licensee BioMed Central Ltd. </text>
<text top="299" left="57" width="495" height="7" font="font3" id="p1_t45" reading_order_no="43" segment_no="11" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution License<a href="http://creativecommons.org/licenses/by/2.0"> (http://creativecommons.org/licenses/by/</a></text>
<text top="309" left="57" width="397" height="7" font="font3" id="p1_t46" reading_order_no="44" segment_no="11" tag_type="text"><a href="http://creativecommons.org/licenses/by/2.0">2.0),</a> which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is cited.</text>
<text top="338" left="57" width="43" height="10" font="font12" id="p1_t47" reading_order_no="45" segment_no="12" tag_type="title"><b>Abstract</b></text>
<text top="359" left="57" width="49" height="8" font="font13" id="p1_t48" reading_order_no="46" segment_no="13" tag_type="text"><b>Introduction</b></text>
<text top="359" left="106" width="191" height="8" font="font14" id="p1_t49" reading_order_no="47" segment_no="13" tag_type="text"> We showed in a previous study that prenylated</text>
<text top="369" left="57" width="240" height="8" font="font14" id="p1_t50" reading_order_no="48" segment_no="13" tag_type="text">proteins play a role in estradiol stimulation of proliferation.</text>
<text top="380" left="57" width="240" height="8" font="font14" id="p1_t51" reading_order_no="49" segment_no="13" tag_type="text">However, these proteins antagonize the ability of estrogen</text>
<text top="390" left="57" width="54" height="8" font="font14" id="p1_t52" reading_order_no="50" segment_no="13" tag_type="text">receptor (ER) </text>
<text top="387" left="111" width="6" height="11" font="font15" id="p1_t53" reading_order_no="51" segment_no="13" tag_type="text">α</text>
<text top="390" left="117" width="181" height="8" font="font14" id="p1_t54" reading_order_no="52" segment_no="13" tag_type="text"> to stimulate estrogen response element (ERE)-</text>
<text top="401" left="57" width="240" height="8" font="font14" id="p1_t55" reading_order_no="53" segment_no="13" tag_type="text">dependent transcriptional activity, potentially through the</text>
<text top="411" left="57" width="240" height="8" font="font14" id="p1_t56" reading_order_no="54" segment_no="13" tag_type="text">formation of a co-regulator complex. The present study</text>
<text top="422" left="57" width="240" height="8" font="font14" id="p1_t57" reading_order_no="55" segment_no="13" tag_type="text">investigates, in further detail, how prenylated proteins modulate</text>
<text top="432" left="57" width="167" height="8" font="font14" id="p1_t58" reading_order_no="56" segment_no="13" tag_type="text">the transcriptional activities mediated by ER</text>
<text top="429" left="224" width="6" height="11" font="font15" id="p1_t59" reading_order_no="57" segment_no="13" tag_type="text">α</text>
<text top="432" left="229" width="42" height="8" font="font14" id="p1_t60" reading_order_no="58" segment_no="13" tag_type="text"> and by ER</text>
<text top="429" left="271" width="5" height="11" font="font15" id="p1_t61" reading_order_no="59" segment_no="13" tag_type="text">β</text>
<text top="432" left="276" width="2" height="8" font="font14" id="p1_t62" reading_order_no="60" segment_no="13" tag_type="text">.</text>
<text top="453" left="57" width="36" height="8" font="font13" id="p1_t63" reading_order_no="61" segment_no="16" tag_type="text"><b>Methods</b></text>
<text top="453" left="92" width="44" height="8" font="font14" id="p1_t64" reading_order_no="62" segment_no="16" tag_type="text"> The ERE-</text>
<text top="450" left="136" width="5" height="11" font="font15" id="p1_t65" reading_order_no="63" segment_no="16" tag_type="text">β</text>
<text top="453" left="141" width="156" height="8" font="font14" id="p1_t66" reading_order_no="64" segment_no="16" tag_type="text">-globin-Luc-SV-Neo plasmid was either</text>
<text top="464" left="57" width="240" height="8" font="font14" id="p1_t67" reading_order_no="65" segment_no="16" tag_type="text">stably transfected into MCF-7 cells or HeLa cells (MELN cells</text>
<text top="474" left="57" width="240" height="8" font="font14" id="p1_t68" reading_order_no="66" segment_no="16" tag_type="text">and HELN cells, respectively) or transiently transfected into</text>
<text top="485" left="57" width="240" height="8" font="font14" id="p1_t69" reading_order_no="67" segment_no="16" tag_type="text">MCF-7 cells using polyethylenimine. Cells deprived of estradiol</text>
<text top="495" left="57" width="240" height="8" font="font14" id="p1_t70" reading_order_no="68" segment_no="16" tag_type="text">were analyzed for ERE-dependent luciferase activity 16 hours</text>
<text top="506" left="57" width="240" height="8" font="font14" id="p1_t71" reading_order_no="69" segment_no="16" tag_type="text">after estradiol stimulation and treatment with FTI-277 (a</text>
<text top="516" left="57" width="240" height="8" font="font14" id="p1_t72" reading_order_no="70" segment_no="16" tag_type="text">farnesyltransferase inhibitor) or with GGTI-298 (a</text>
<text top="527" left="57" width="240" height="8" font="font14" id="p1_t73" reading_order_no="71" segment_no="16" tag_type="text">geranylgeranyltransferase I inhibitor). In HELN cells, the effect of</text>
<text top="537" left="57" width="240" height="8" font="font14" id="p1_t74" reading_order_no="72" segment_no="16" tag_type="text">prenyltransferase inhibitors on luciferase activity was compared</text>
<text top="548" left="57" width="240" height="8" font="font14" id="p1_t75" reading_order_no="73" segment_no="16" tag_type="text">after transient transfection of plasmids coding either the full-</text>
<text top="558" left="57" width="37" height="8" font="font14" id="p1_t76" reading_order_no="74" segment_no="16" tag_type="text">length ER</text>
<text top="555" left="94" width="6" height="11" font="font15" id="p1_t77" reading_order_no="75" segment_no="16" tag_type="text">α</text>
<text top="558" left="99" width="68" height="8" font="font14" id="p1_t78" reading_order_no="76" segment_no="16" tag_type="text">, the full-length ER</text>
<text top="555" left="167" width="5" height="11" font="font15" id="p1_t79" reading_order_no="77" segment_no="16" tag_type="text">β</text>
<text top="558" left="172" width="81" height="8" font="font14" id="p1_t80" reading_order_no="78" segment_no="16" tag_type="text">, the AF-1-deleted ER</text>
<text top="555" left="253" width="6" height="11" font="font15" id="p1_t81" reading_order_no="79" segment_no="16" tag_type="text">α</text>
<text top="558" left="259" width="38" height="8" font="font14" id="p1_t82" reading_order_no="80" segment_no="16" tag_type="text"> or the AF-</text>
<text top="569" left="57" width="52" height="8" font="font14" id="p1_t83" reading_order_no="81" segment_no="16" tag_type="text">2-deleted ER</text>
<text top="566" left="109" width="6" height="11" font="font15" id="p1_t84" reading_order_no="82" segment_no="16" tag_type="text">α</text>
<text top="569" left="114" width="86" height="8" font="font14" id="p1_t85" reading_order_no="83" segment_no="16" tag_type="text">. The presence of ER</text>
<text top="566" left="201" width="6" height="11" font="font15" id="p1_t86" reading_order_no="84" segment_no="16" tag_type="text">α</text>
<text top="569" left="206" width="91" height="8" font="font14" id="p1_t87" reading_order_no="85" segment_no="16" tag_type="text"> was then detected by</text>
<text top="579" left="57" width="240" height="8" font="font14" id="p1_t88" reading_order_no="86" segment_no="16" tag_type="text">immunocytochemistry in either the nuclei or the cytoplasms of</text>
<text top="359" left="315" width="87" height="8" font="font14" id="p1_t89" reading_order_no="87" segment_no="14" tag_type="text">MCF-7 cells. Finally, </text>
<text top="359" left="403" width="94" height="8" font="font16" id="p1_t90" reading_order_no="88" segment_no="14" tag_type="text"><i>Clostridium botulinum </i></text>
<text top="359" left="497" width="59" height="8" font="font14" id="p1_t91" reading_order_no="89" segment_no="14" tag_type="text">C3 exoenzyme</text>
<text top="369" left="315" width="240" height="8" font="font14" id="p1_t92" reading_order_no="90" segment_no="14" tag_type="text">treatment was used to determine the involvement of Rho</text>
<text top="380" left="315" width="173" height="8" font="font14" id="p1_t93" reading_order_no="91" segment_no="14" tag_type="text">proteins in ERE-dependent luciferase activity.</text>
<text top="401" left="315" width="31" height="8" font="font13" id="p1_t94" reading_order_no="92" segment_no="15" tag_type="text"><b>Results</b></text>
<text top="401" left="346" width="210" height="8" font="font14" id="p1_t95" reading_order_no="93" segment_no="15" tag_type="text"> FTI-277 and GGTI-298 only stimulate ERE-dependent</text>
<text top="411" left="315" width="240" height="8" font="font14" id="p1_t96" reading_order_no="94" segment_no="15" tag_type="text">luciferase activity in stably transfected MCF-7 cells. They</text>
<text top="422" left="315" width="81" height="8" font="font14" id="p1_t97" reading_order_no="95" segment_no="15" tag_type="text">stimulate both ER</text>
<text top="419" left="396" width="6" height="11" font="font15" id="p1_t98" reading_order_no="96" segment_no="15" tag_type="text">α</text>
<text top="422" left="402" width="82" height="8" font="font14" id="p1_t99" reading_order_no="97" segment_no="15" tag_type="text">-mediated and ER</text>
<text top="419" left="484" width="5" height="11" font="font15" id="p1_t100" reading_order_no="98" segment_no="15" tag_type="text">β</text>
<text top="422" left="489" width="67" height="8" font="font14" id="p1_t101" reading_order_no="99" segment_no="15" tag_type="text">-mediated ERE-</text>
<text top="432" left="315" width="240" height="8" font="font14" id="p1_t102" reading_order_no="100" segment_no="15" tag_type="text">dependent luciferase activity in HELN cells, in the presence of</text>
<text top="443" left="315" width="240" height="8" font="font14" id="p1_t103" reading_order_no="101" segment_no="15" tag_type="text">and in the absence of estradiol. The roles of both AF-1 and AF-</text>
<text top="453" left="315" width="159" height="8" font="font14" id="p1_t104" reading_order_no="102" segment_no="15" tag_type="text">2 are significant in this effect. Nuclear ER</text>
<text top="450" left="474" width="6" height="11" font="font15" id="p1_t105" reading_order_no="103" segment_no="15" tag_type="text">α</text>
<text top="453" left="480" width="76" height="8" font="font14" id="p1_t106" reading_order_no="104" segment_no="15" tag_type="text"> is decreased in the</text>
<text top="464" left="315" width="240" height="8" font="font14" id="p1_t107" reading_order_no="105" segment_no="15" tag_type="text">presence of prenyltransferase inhibitors in MCF-7 cells, again in</text>
<text top="474" left="315" width="241" height="8" font="font14" id="p1_t108" reading_order_no="106" segment_no="15" tag_type="text">the presence of and in the absence of estradiol. By contrast,</text>
<text top="485" left="315" width="60" height="8" font="font14" id="p1_t109" reading_order_no="107" segment_no="15" tag_type="text">cytoplasmic ER</text>
<text top="482" left="375" width="6" height="11" font="font15" id="p1_t110" reading_order_no="108" segment_no="15" tag_type="text">α</text>
<text top="485" left="381" width="175" height="8" font="font14" id="p1_t111" reading_order_no="109" segment_no="15" tag_type="text"> is mainly decreased after treatment with FTI-</text>
<text top="495" left="315" width="240" height="8" font="font14" id="p1_t112" reading_order_no="110" segment_no="15" tag_type="text">277, in the presence of and in the absence of estradiol. The</text>
<text top="506" left="315" width="240" height="8" font="font14" id="p1_t113" reading_order_no="111" segment_no="15" tag_type="text">involvement of Rho proteins in ERE-dependent luciferase</text>
<text top="516" left="315" width="165" height="8" font="font14" id="p1_t114" reading_order_no="112" segment_no="15" tag_type="text">activity in MELN cells is clearly established.</text>
<text top="537" left="315" width="50" height="8" font="font13" id="p1_t115" reading_order_no="113" segment_no="17" tag_type="text"><b>Conclusions</b></text>
<text top="537" left="366" width="190" height="8" font="font14" id="p1_t116" reading_order_no="114" segment_no="17" tag_type="text"> Together, these results demonstrate that</text>
<text top="548" left="315" width="240" height="8" font="font14" id="p1_t117" reading_order_no="115" segment_no="17" tag_type="text">prenylated proteins (at least RhoA, RhoB and/or RhoC)</text>
<text top="558" left="315" width="116" height="8" font="font14" id="p1_t118" reading_order_no="116" segment_no="17" tag_type="text">antagonize the ability of ER</text>
<text top="555" left="431" width="6" height="11" font="font15" id="p1_t119" reading_order_no="117" segment_no="17" tag_type="text">α</text>
<text top="558" left="437" width="37" height="8" font="font14" id="p1_t120" reading_order_no="118" segment_no="17" tag_type="text"> and ER</text>
<text top="555" left="473" width="5" height="11" font="font15" id="p1_t121" reading_order_no="119" segment_no="17" tag_type="text">β</text>
<text top="558" left="478" width="78" height="8" font="font14" id="p1_t122" reading_order_no="120" segment_no="17" tag_type="text"> to stimulate ERE-</text>
<text top="569" left="315" width="240" height="8" font="font14" id="p1_t123" reading_order_no="121" segment_no="17" tag_type="text">dependent transcriptional activity, potentially acting through</text>
<text top="579" left="315" width="169" height="8" font="font14" id="p1_t124" reading_order_no="122" segment_no="17" tag_type="text">both AF-1 and AF-2 transcriptional activities.</text>
<text top="601" left="57" width="40" height="7" font="font2" id="p1_t125" reading_order_no="123" segment_no="18" tag_type="text"><b>Keywords: </b></text>
<text top="601" left="97" width="371" height="7" font="font3" id="p1_t126" reading_order_no="124" segment_no="18" tag_type="text">estrogen receptor, farnesyltransferase inhibitor, geranylgeranyltransferase inhibitor, Rho proteins, transcription</text>
<text top="640" left="57" width="64" height="10" font="font12" id="p1_t127" reading_order_no="125" segment_no="19" tag_type="title"><b>Introduction</b></text>
<text top="651" left="57" width="177" height="9" font="font17" id="p1_t128" reading_order_no="126" segment_no="21" tag_type="text">Both estrogen receptor (ER) subtypes, ER</text>
<text top="649" left="234" width="6" height="12" font="font18" id="p1_t129" reading_order_no="127" segment_no="21" tag_type="text">α</text>
<text top="651" left="240" width="34" height="9" font="font17" id="p1_t130" reading_order_no="128" segment_no="21" tag_type="text"> and ER</text>
<text top="649" left="274" width="5" height="12" font="font18" id="p1_t131" reading_order_no="129" segment_no="21" tag_type="text">β</text>
<text top="651" left="279" width="18" height="9" font="font17" id="p1_t132" reading_order_no="130" segment_no="21" tag_type="text">, are</text>
<text top="663" left="57" width="168" height="9" font="font17" id="p1_t133" reading_order_no="131" segment_no="21" tag_type="text">ligand-activated transcription factors. ER</text>
<text top="660" left="225" width="6" height="12" font="font18" id="p1_t134" reading_order_no="132" segment_no="21" tag_type="text">α</text>
<text top="663" left="231" width="66" height="9" font="font17" id="p1_t135" reading_order_no="133" segment_no="21" tag_type="text"> is the major ER</text>
<text top="675" left="57" width="241" height="9" font="font17" id="p1_t136" reading_order_no="134" segment_no="21" tag_type="text">in mammary epithelium and is an important regulator of cell</text>
<text top="687" left="57" width="240" height="9" font="font17" id="p1_t137" reading_order_no="135" segment_no="21" tag_type="text">growth, differentiation and malignant transformation. After</text>
<text top="640" left="315" width="241" height="9" font="font17" id="p1_t138" reading_order_no="136" segment_no="20" tag_type="text">binding to estrogen, the receptors associate with specific</text>
<text top="651" left="315" width="240" height="9" font="font17" id="p1_t139" reading_order_no="137" segment_no="20" tag_type="text">estrogen response elements (EREs) within the promoters</text>
<text top="663" left="315" width="241" height="9" font="font17" id="p1_t140" reading_order_no="138" segment_no="20" tag_type="text">of estrogen-regulated genes or the receptors affect the</text>
<text top="675" left="315" width="240" height="9" font="font17" id="p1_t141" reading_order_no="139" segment_no="20" tag_type="text">activity of other transcription factor complexes such as AP-</text>
<text top="687" left="315" width="240" height="9" font="font17" id="p1_t142" reading_order_no="140" segment_no="20" tag_type="text">1 (Jun–Fos). The two ER subtypes share affinity for the</text>
<text top="714" left="57" width="499" height="7" font="font3" id="p1_t143" reading_order_no="141" segment_no="22" tag_type="footnote">DCC-FCS = dextran-coated charcoal treated fetal calf serum; DMEM = Dulbecco's modified Eagle's medium; E2 = estradiol; ER = estrogen receptor; </text>
<text top="724" left="57" width="499" height="7" font="font3" id="p1_t144" reading_order_no="142" segment_no="22" tag_type="footnote">ERE = estrogen response element; FCS = fetal calf serum; FTI-277 = farnesyltransferase inhibitor; GGTI-298 = geranylgeranyltransferase inhibitor; </text>
<text top="733" left="57" width="338" height="7" font="font3" id="p1_t145" reading_order_no="143" segment_no="22" tag_type="footnote">MNAR = modulator of non-genomic activity of estrogen receptor; PBS = phosphate-buffered saline.</text>
</page>
</pdf2xml>
